Recent director dealings and insider transactions at West Pharmaceutical Services, Inc. (WST),
from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
Date
Insider
Type
Shares
2026-06-30
Haugen Janet Brutschea
BUY
46
2026-05-12
Campbell Shane Alden
SELL
474
2026-05-12
Campbell Shane Alden
SELL
296
2026-05-12
Campbell Shane Alden
SELL
135
2026-05-12
Campbell Shane Alden
BUY
474
2026-05-12
Campbell Shane Alden
SELL
84
2026-05-12
Campbell Shane Alden
BUY
296
2026-05-04
Friel Robert F
BUY
791
2026-05-04
Feehery William F
BUY
791
2026-05-04
Pucci Paolo
BUY
791
Graham NCAV AnalysisAbove net-net level
Current Assets$1.98B
Less: Total Liabilities−$1.09B
= Net Current Asset Value$884.2M
NCAV Per Share$11.7356
Current Price$357.69
Price / NCAV30.48×
Margin of Safety-2947.9%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta1.159
Dividend/yrNone
52W High$367.66
52W Low$221.50
52-Week Range
$221.50Now$367.66
94% through annual range
From 52W High−2.5%
From 52W Low+61.8%
📖 Plain English Summary
West Pharmaceutical Services, Inc. is at 94% of its 52-week range. Beta 1.159 — moves broadly in line with the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for WST🟢 Bullish⬜ Neutral🔴 Bearish
🤖
DipBuster AI Analysis — WST
Heuristic · balance sheet, insider filings, price data, academic research
West Pharmaceutical Services, Inc. — DipBuster Score 16/100
Graham value assessment, NCAV analysis, price zones...
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products…